Methotrexate
| Evidence Level: L5 | Predicted Indications: 69 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Methotrexate |
| DrugBank ID | DB00563 |
| Brand Names (EU) | Jylamvo, Nordimet |
| Evidence Level | L5 |
| Predicted Indications | 69 |
| Top Prediction Score | 99.46% |
Approved Indication (EMA)
In rheumatological and dermatological diseases Active rheumatoid arthritis in adult patients. Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate. Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | rheumatoid arthritis | 99.46% | DL |
| 2 | pulmonary blastoma | 99.45% | DL |
| 3 | primary pulmonary lymphoma | 99.45% | DL |
| 4 | small cell lung carcinoma | 99.43% | DL |
| 5 | well-differentiated fetal adenocarcinoma of the lung | 99.42% | DL |
| 6 | acute lymphoblastic/lymphocytic leukemia | 99.36% | DL |
| 7 | Hodgkins lymphoma | 99.32% | DL |
| 8 | rhabdomyosarcoma (disease) | 99.25% | DL |
| 9 | folliculotropic mycosis fungoides | 99.23% | DL |
| 10 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.23% | DL |
| 11 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.23% | DL |
| 12 | parameningeal embryonal rhabdomyosarcoma | 99.21% | DL |
| 13 | acute lymphoblastic leukemia (disease) | 99.21% | DL |
| 14 | botryoid-type embryonal rhabdomyosarcoma of the vagina | 99.21% | DL |
| 15 | embryonal extrahepatic bile duct rhabdomyosarcoma | 99.17% | DL |
| 16 | extrahepatic bile duct rhabdomyosarcoma | 99.15% | DL |
| 17 | prostate embryonal rhabdomyosarcoma | 99.14% | DL |
| 18 | mycosis fungoides and variants | 99.04% | DL |
| 19 | brachydactyly-syndactyly syndrome | 99.02% | DL |
| 20 | liver sarcoma | 98.99% | DL |
Showing top 20 of 69 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.